Insider Trading Alert - BCR, CYS And MMM Traded By Insiders - TheStreet

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 29, 2014, 60 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.00 to $206,654,400.00.

Highlighted Stocks Traded by Insiders:

CR Bard (BCR) - FREE Research Report

Naughton Gail K, who is Director at CR Bard, sold 400 shares at $158.70 on Oct. 29, 2014. Following this transaction, the Director owned 2,159 shares meaning that the stake was reduced by 15.63% with the 400-share transaction.

The shares most recently traded at $160.01, up $1.31, or 0.82% since the insider transaction. Historical insider transactions for CR Bard go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 974
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 974
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 974

The average volume for CR Bard has been 518,600 shares per day over the past 30 days. CR Bard has a market cap of $12.0 billion and is part of the health care sector and health services industry. Shares are up 19.22% year-to-date as of the close of trading on Wednesday.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The stock currently has a dividend yield of 0.55%. The company has a P/E ratio of 15.8. Currently, there are 2 analysts who rate CR Bard a buy, 2 analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCR - FREE

TheStreet Quant Ratings

rates CR Bard as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, expanding profit margins and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

CR Bard Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CYS Investments (CYS) - FREE Research Report

Cleary Richard E, who is COO and Assistant Secretary at CYS Investments, sold 18,000 shares at $8.90 on Oct. 29, 2014. Following this transaction, the COO and Assistant Secretary owned 153,050 shares meaning that the stake was reduced by 10.52% with the 18,000-share transaction.

The shares most recently traded at $8.88, down $0.02, or 0.28% since the insider transaction. Historical insider transactions for CYS Investments go as follows:

  • 4-Week # shares sold: 6,015
  • 12-Week # shares bought: 34,248
  • 12-Week # shares sold: 6,015
  • 24-Week # shares bought: 34,248
  • 24-Week # shares sold: 6,015

The average volume for CYS Investments has been 2.0 million shares per day over the past 30 days. CYS Investments has a market cap of $1.5 billion and is part of the financial sector and real estate industry. Shares are up 19.7% year-to-date as of the close of trading on Wednesday.

CYS Investments, Inc., a specialty finance company, makes leveraged investments in whole-pool residential mortgage pass-through securities where the principal and interest payments are guaranteed. The stock currently has a dividend yield of 13.29%. The company has a P/E ratio of 7.3. Currently, there are 7 analysts who rate CYS Investments a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYS - FREE

TheStreet Quant Ratings

rates CYS Investments as a

hold

. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full

CYS Investments Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3M (MMM) - FREE Research Report

Lindekugel Jon T, who is Senior Vice President at 3M, sold 1,459 shares at $150.39 on Oct. 29, 2014. Following this transaction, the Senior Vice President owned 780 shares meaning that the stake was reduced by 65.16% with the 1,459-share transaction.

The shares most recently traded at $150.58, up $0.19, or 0.12% since the insider transaction. Historical insider transactions for 3M go as follows:

  • 4-Week # shares sold: 54,226
  • 12-Week # shares bought: 6,625
  • 12-Week # shares sold: 54,226
  • 24-Week # shares bought: 6,625
  • 24-Week # shares sold: 58,461

The average volume for 3M has been 2.8 million shares per day over the past 30 days. 3M has a market cap of $97.9 billion and is part of the industrial goods sector and industrial industry. Shares are up 7.67% year-to-date as of the close of trading on Wednesday.

3M Company operates as a diversified technology company worldwide. The stock currently has a dividend yield of 2.26%. The company has a P/E ratio of 20.7. Currently, there are 7 analysts who rate 3M a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMM - FREE

TheStreet Quant Ratings

rates 3M as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, notable return on equity and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

3M Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null